Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome

Bone Marrow Transplantation volume 49, pages 1360–1365 (2014)Cite this article

Subjects

Abstract

We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with MF/SS reported to the Center for the International Blood and Marrow Transplant from 2000–2009. Median time from diagnosis to transplant was 30 (4–206) months and most subjects were with multiply relapsed/ refractory disease. The majority (64%) received non-myeloablative conditioning (NST) or reduced intensity conditioning (RIC). NST/RIC recipients were older in age compared with myeloablative recipients (median age 51 vs 44 years, P=0.005) and transplanted in recent years. Non-relapse mortality (NRM) at 1 and 5 years was 19% (95% confidence interval (CI) 12–27%) and 22% (95% CI 15–31%), respectively. Risk of disease progression was 50% (95% CI 41–60%) at 1 year and 61% (95% CI 50–71%) at 5 years. PFS at 1 and 5 years was 31% (95% CI 22–40%) and 17% (95% CI 9–26%), respectively. OS at 1 and 5 years was 54% (95% CI 45–63%) and 32% (95% CI 22–44%), respectively. Allogeneic HCT in MF/SS results in 5-year survival in approximately one-third of patients and of those, half remain disease-free.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M et al. Histopathological staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372–382.

    Article  CAS  Google Scholar 

  2. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730–4739.

    Article  Google Scholar 

  3. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991; 7: 133–137.

    CAS  PubMed  Google Scholar 

  4. Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114: 624–631.

    Article  CAS  Google Scholar 

  5. Duarte RF, Schmitz N, Servitje O, Sureda A . Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 2008; 41: 597–604.

    Article  CAS  Google Scholar 

  6. Molina A, Zain J, Arber DA, Angelopolou M, O’Donnell M, Murata-Collins J et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23: 6163–6171.

    Article  Google Scholar 

  7. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sezary syndrome: a retrospective analysis of the lymphoma working party of the european group for blood and marrow transplantation. J Clin Oncol 2010; 28: 4492–4499.

    Article  Google Scholar 

  8. Lechowicz M, Agovi M, Carreras J, Lazarus HM, Laport GG, Montoto S et al. Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review. Blood 2010; 116: 2246 (Abstract 364).

    Google Scholar 

  9. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  Google Scholar 

  10. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM . Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 521–525.

    Article  CAS  Google Scholar 

  11. Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22: 1608–1613.

    Article  CAS  Google Scholar 

  12. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE . A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant 2009; 15: 982–990.

    Article  Google Scholar 

  13. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–1722.

    Article  CAS  Google Scholar 

  14. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W et al. Total Skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sézary Syndrome. J Clin Oncol 2010; 28: 2365–2372.

    Article  Google Scholar 

  15. De Masson A, Beylot-Barry M, Bouaziz J-D, Peffault de Latour R, Aubin F, Garciaz S et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica 2014; 99: 527–534.

    Article  Google Scholar 

Download references

Acknowledgements

The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24 CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement U10 HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from Allos Therapeutics, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Celgene Corporation; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;Gentium SpA; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.

Author information

Authors and Affiliations

  1. Emory University Hospital, Atlanta, GA, USA

    M J Lechowicz

  2. Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA

    H M Lazarus

  3. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA

    J Carreras & P N Hari

  4. Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA

    G G Laport

  5. Dana Farber Cancer Institute, Boston, MA, USA

    C S Cutler

  6. Our Lady of Mercy Medical Center, Bronx, NY, USA

    P H Wiernik

  7. Pediatric Hematology/Oncology/BMT, All Children’s Hospital, St. Petersburg, FL, USA

    G A Hale

  8. South Florida Bone Marrow Stem Cell Transplant Institute, Boynton Beach, FL, USA

    D Maharaj

  9. Division of Experimental Medicine, Department of Medicine, Section of Hematology, Imperial College, London, UK

    R P Gale

  10. Calvary Mater Newcastle, HAPS-Pathology North, University of Newcastle, New South Wales, Australia,

    P A Rowlings

  11. South Texas Veterans Health Care System and University of Texas Health Science Center San Antonio, San Antonio, TX, USA

    C O Freytes

  12. Baylor University Medical Center, Dallas, TX, USA

    A M Miller

  13. Division of Hematology/Oncology, The Nebraska Medical Center, Omaha, NE, USA

    J M Vose

  14. Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA

    R T Maziarz

  15. Barts Cancer Institute, Queen Mary University of London, London, UK

    S Montoto

  16. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    D G Maloney

Authors
  1. M J Lechowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Carreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G G Laport
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C S Cutler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P H Wiernik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G A Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Maharaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R P Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P A Rowlings
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C O Freytes
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A M Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J M Vose
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R T Maziarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. S Montoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. D G Maloney
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. P N Hari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P N Hari.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lechowicz, M., Lazarus, H., Carreras, J. et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 49, 1360–1365 (2014). https://doi.org/10.1038/bmt.2014.161

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.161

This article is cited by

Search

Advanced search

Quick links